In 299 patients with mismatch repair-deficient advanced or recurrent endometrial cancer, first-line pembrolizumab beat carboplatin-paclitaxel on progression-free survival (median 38·2 vs 8·4 months; HR 0·57); overall survival not significant at interim analysis.
RCTn = 299
Slomovitz et al. First-line pembrolizumab versus carboplatin plus paclitaxel in participants with mismatch repair-deficient advanced or recurrent endometrial cancer (KEYNOTE-C93/GOG-3064/ENGOT-en15): interim analysis of a multicentre, open-label, randomised, active-comparator controlled, phase 3 trial